Many of the secrets of why precancerous conditions sometimes become cancerous are hidden in cells’ genes. At Dana-Farber, researchers are collecting tissue samples to see if they can pry open those secrets and unlock new treatment options for certain types of blood cancers and other blood disorders. They’re also exploring whether tumor DNA floating in … Read more
For Anna Heard, the fall of 2002 was a season of change. Set to move to Boston in September to begin a master’s program at Harvard T. H. Chan School of Public Health, Heard, then 29, had a routine physical in Washington, D.C., before starting the academic year. Although her bloodwork looked “a bit funny,” … Read more
It might sound counterintuitive, but not every patient comes to Dana-Farber for cancer treatment. For example, the Institute’s experts regularly see patients seeking help with benign (non-cancerous) blood disorders. Benign blood disorders such as anemia and sickle cell disease are often treated at cancer centers because such institutions are home to experts in hematology, which … Read more
By Kathleen Barton When you get diagnosed with cancer, it kicks your butt – both the physical aspects of chemo and the general inertia that comes with this new thing you’re living with. Before my diagnosis, I was active – working, volunteering, exercising, and spending time with friends. Then some bruising and fatigue led me … Read more
Active in physical pursuits and a world traveler, Harry Beskind, MD, was surprised when he started feeling tired while on a bike ride in 2014. He had just returned home from a river trip to Portugal with his wife, and Beskind, then 82, was having trouble riding up hills on his bike. “I thought I was just … Read more
With new research in immunotherapy and targeted therapy, treatment options for blood cancer patients are rapidly expanding. Combination therapies have also caused much excitement among researchers and physicians, and ongoing clinical trials are continuing to look at new strategies that use multiple drugs for fighting these diseases. In this Cancer Conversations podcast episode, Irene Ghobrial, … Read more
The last two years have been very exciting for blood cancer research; many new targeted therapies and immunotherapies are improving treatment outcomes for patients with lymphoma, leukemia and multiple myeloma. “We’re starting to see a lot of hematologic malignancies benefit from immunotherapy,” says Irene Ghobrial, MD. “The excitement is there for so many trials and … Read more
Chris Potter was not a fan of flying, until a group of pilots he had never met transported him to his life-saving care team. Potter, then 42, was struggling through a relapse of acute lymphocytic leukemia in 2011. His cancer was not responding to treatment, and he required at least a temporary remission to handle … Read more
When Roy Jann was diagnosed with cancer in 2013, it never crossed his mind that he would be a model for the life-saving potential of venetoclax, a new type of cancer drug that had recently entered human testing. The first inkling that something was amiss had come a few weeks earlier, while Jann was biking … Read more
Updated April 13, 2015 Venetoclax, a new type of cancer drug known as a Bcl-2 inhibitor, is showing great promise against a poor-prognosis form of chronic lymphocytic leukemia (CLL), and could work in other cancers as well. Venetoclax, formerly known as ABT-199, attacks the protein molecule, Bcl-2, that allows cancer cells to survive despite signals … Read more
While lymphomas and lymphocytic leukemias are both blood disorders, they are not the same disease. The main difference between lymphomas and lymphocytic leukemias is the location of the cancer cells. In leukemia, they’re found primarily in the bone marrow and blood; in lymphoma, they exist mainly in the lymph system, a network of tissues and … Read more
The past two years have seen a surge of new treatments for blood cancers, such as lymphoma, leukemia and multiple myeloma. Research on the genetic flaws underlying specific cancer types has led to new precision drugs such as ibrutinib and idelalisib and new immunotherapy agents that are improving outcomes in many patients with difficult-to-treat forms … Read more
Hodgkin and non-Hodgkin lymphoma are the two main types of lymphoma, a cancer that affects the lymphatic system. The lymphatic system produces and transports white blood cells to fight infection. While they have many characteristics in common, there are some significant differences between Hodgkin and non-Hodgkin lymphoma, including the age groups they affect, how they … Read more
To mark its 50th anniversary, the American Society of Clinical Oncology (ASCO) invited physicians, patients, and the public to name the most important advances in clinical cancer research in the past half century. From more than 2,000 responses, the top choice was a cure for advanced Hodgkin lymphoma developed by scientists at the National Cancer … Read more
It looked like a scientific dead end – a clinical trial that found no benefit to a potential drug for a form of leukemia. But, like police detectives working a cold case, Dana-Farber scientists gathered hundreds of tissue samples that had been collected for the study – most of them languishing in laboratory cabinets, destined … Read more
By Elise Renner There’s a 1-in-12 chance that this is the month yours or your loved one’s cancer is recognized—odds better than the survival rates for some of these diseases. Some months, like October, boast big names like breast cancer. Others, like September, are crowded with lesser-known branches of the disease. “Cancer apparel,” including ribbons … Read more
Waldenström’s macroglobulinemia (Waldenström’s) is a slow-growing type of non-Hodgkin lymphoma marked by abnormal levels of an antibody called macroglobulin (IgM). Also known as lymphoplasmacytic lymphoma, Waldenström’s mostly forms in the bone marrow and can hinder the growth of normal blood cells, which can lead to anemia as well as a weakened immune system. Waldenström’s sometimes … Read more
It’s commonly thought that targeted therapy for cancer requires the development of separate drugs for each type and subtype of cancer. The recent approval of the drug ibrutinib (Imbruvica®), however, for Waldenström’s macroglobulinemia (a rare form of lymphoma) shows the opposite to be true: a single agent can be effective against multiple types of cancers, providing … Read more
Rapid Heme Panel, a new quick-turnaround genetic diagnostic test, at Dana-Farber/Brigham and Women’s Cancer Center (DF/BWCC), offers some patients with aggressive blood cancers faster diagnoses, and treatments. Instead of sending blood samples to different laboratories for tests that return results in two weeks or more, Rapid Heme Panel puts the results in doctors’ hands in … Read more
In the treatment of blood cancers and disorders, doctors and researchers are focusing their sights on the immune system and how to bolster its ability to fight off diseases like leukemia, lymphoma and multiple myeloma. “Understanding how you control the immune system is a big theme in treatment for these diseases,” says David A. Williams, … Read more